Efficacy and safety of aerosolized tobramycin in cystic fibrosis

@article{Pai2001EfficacyAS,
  title={Efficacy and safety of aerosolized tobramycin in cystic fibrosis},
  author={Vinita B. Pai and Milap C. Nahata},
  journal={Pediatric Pulmonology},
  year={2001},
  volume={32}
}
Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by limiting systemic absorption. Aerosolized tobramycin doses ranging from 80 mg twice or three times daily to 600 mg three times daily have been used in various clinical trials. At an 80‐mg dose, preservation of pulmonary function with little or no improvement over the baseline was reported. Tobramycin… 
Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
  • R. Dopfer, P. Brand, +5 authors R. Siekmeier
  • Medicine
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • 2007
TLDR
The data suggest that controlled inhalation can significantly reduce the amount of a drug required for therapy, the inhalation time required for drug deposition, and the variability of pulmonary dosage, and it seems probable that controlled breathing can improve the antibiotic prevention of pulmonary infection.
Inhaled Tobramycin (TOBI®)
TLDR
In conclusion, TSI provides an effective means of delivering tobramycin to the lungs of patients with cystic fibrosis with chronic P. aeruginosa infection, improving lung function and sputum P. aerospace density, and is generally well tolerated in clinical trials.
Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.
TLDR
Compared with the standard nebulizer, the AeroDose safely achieved an approximately threefold greater efficiency in the delivery of TSI to the lungs in less than half the time.
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.
  • V. Ahya, A. Doyle, +7 authors R. Kotloff
  • Medicine
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • 2005
TLDR
This is the first report of a lung transplant recipient who developed renal failure and vestibular injury after receiving inhaled tobramycin, and potential mechanisms that may promote systemic toxicity in transplant recipients are discussed.
Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
TLDR
Simulation showed that steady-state concentrations of tobramycin are lower in pediatric patients 6 months to 6 years than those in patients over 6 years; however, systemic exposure is not predictive of clinical efficacy due to direct dosing at the infection site.
Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.
TLDR
OD tobramycin inhalation of the double standard BID dose with a controlled-inhalation and conventional nebulizer resulted in similar pharmacokinetics in the doses given, with serum levels below the toxic limit.
Aerosolized Antibiotics
Aerosolized antibiotics potentially enable delivery of drugs directly at the site of lung infection with limited systemic side effects. Progress in understanding determinants of pharmacokinetics and
Clinical pharmacology of tobramycin in infants and children
TLDR
The aim of this study is to review published data on tobramycin dosing, efficacy, safety, effects, adverse-effects, drug-interactions, treatment optimization, trials, meningitis, pharmacodynamics, pharmacokinetics, and bacterial-resistance in infants and children.
Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
TLDR
CFD modelling showed that high concentrations of inhaled tobramycin are indeed delivered to the airways, with the Akita® system being twice as efficient as the PARI-LC® system.
Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
  • L. Patatanian
  • Medicine
    The Pediatric infectious disease journal
  • 2006
TLDR
An adolescent with cystic fibrosis, renal failure and a serum concentration of 13.4 mg/dL who was diagnosed with profound sensorineural hearing loss after 3 weeks of inhaled tobramycin therapy is diagnosed.
...
1
2
3
4
5
...